TheraRadar
← Back
Data updated: Jun 28, 2026

BPI LABS

Specialty
Pharmaceuticals

BPI LABS is a specialty pharmaceutical company with 11 FDA-approved products.

2014
Since
11
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
1 Small Molecules

BPI LABS's Key Drugs

BPI LABS's core commercial portfolio centers on ABLYSINOL — its most strategically important drugs approved in the last 15 years.

ABLYSINOL
Cardiovascular

Hypertrophic Obstructive Cardiomyopathy

Approved 2018

BPI LABS's Recent FDA Approvals

BPI LABS secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

EPINEPHRINE NDA
2026-03-30
epinephrine
1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
EPINEPHRINE NDA
2025-03-13
epinephrine
1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.

BPI LABS's Therapeutic Areas

Disease areas where BPI LABS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

BPI LABS Pipeline Snapshot

Active clinical trials for BPI LABS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ABLYSINOL leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling